We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need.
Seladelpar is a potent, selective, orally active PPARδ agonist in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (PBC). The PBC program is on hold. Seladelpar has received an orphan designation from the U.S. Food and Drug Administration and the PRIority MEdicine (PRIME) status from the European Medicines Agency.
7575 Gateway Blvd
Newark, CA 94560 US